European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 07, 2020

A Review Study On Relationship Among Covid-19 And Inflammation

Mr.Ponnazhagan[1], Dr.Amarendiran[2]

[1]Tutor, Meenakshi Academy of Higher Education and Research
[2]Senior Resident, Meenakshi Academy of Higher Education and Research

Email: [1]ponnazhagan@mmchri.ac.in

ABSTRACT: In reality, numerous research works have begun to report the metabolic function of COVID-19 shifts. Characteristically characterised are I decline in low-density (LDL-c) and high-density (HDL-c) cholesterol lipoproteins, (later proportionate with the gravity of the symptoms), and (ii) a mild rise in the populating T-assistance cell populations (CD3+T, CD4+T) and (iii) CD8+T lymphopenia. Further, in seriously ill patients the overall counts of White Blood Cells (WBC) is considerably higher, with a macrophage activation syndrome that was supported by the existence of the bronchoalveolar monocyte recruitment chemokines.

Keywords: COVID 19, Inflammation, Pandemic

BACKGROUND

Statistics suggest that a good number of COVID-19 patients survive and only a small percentage of them die. The major role of the immune system in deciding the destiny of COVID-19 patients were recorded through research. The major caus of mortality in patients with COVID-19.1 Inflammatory cytokine (MCI-10, IL-6, IL-8), G-CSF and GM-CSF (colony stimulating factors) as well as inflammatory chemical compounds (GCP-1, IP10, MIP1α) and their destructive function in inflammatory monocytes and macrophages, the findings have shown that destructive and extreme inflammation are the leading causes of death [1–4]. The two major causes of extreme COVID-19.1 are Acute Respiratory Distress Syndrome (ARDS) and Cytokine storma Recently, Liao etal. with single-cell RNA sequence, researched and found very important results of bronchoalveolar lavage fluid. For patients suffering from serious diseases the analysis showed that alveolar macrophages resident in the lung tissue were eliminated but that the lungs were accumulated with monocyte inflammatory macrophages. Inflammatory macrophages predisposing recruitment of other inflammatory cells to lung tissue and the growth of ARDS, through the use of various chemokines and cytokines. Curcumin is an active component of the rhizome of the turmeric turmeric Curcuma longa with the chemical name Diffuloylmethane and the chemical formula C21H20O6.5 Curcumin, which makes up about 2 percent to around 8 percent turmeric compounds, is a key element in the yellow and golden colour of turmeric [5–7]. The structural part of curcumin, made up of two chromophore aryl buten-2 (feruloyl), followed by a group of methylene in 1910, was introduced as diffuloylmethane.6 Curcumin was a lipophilic fluorescent molecule with phenolic groups and double bonds conjugation. It is of poor toxicity, but has a wide spectrum of pharmacological substances. Additional acts for turmeric have been reported: reduced lipid blood, protected liver, liposygenase inhibitory, inhibited cyclooxygenase, proteases inhibited, free radicals removed, lipid peroxidation blocked, plateles aggregation reduced, digestion improved by bile flow increased and cytokines and other inflammatory components altered. Many chronic conditions have found to be caused by a desequilibrium of inflammatory reactions. Recent

scientific evidence indicates that turmeric is highly anti-inflammatory, particularly curcumin. Thus, turmeric and curcumin are used to cure multiple inflammatory diseases. It is no wonder.

COVID 19 AND INFECTIONS

COVID-19 has resulted in more than 39 million contaminated infections and 1 million deaths worldwide since first recorded in the Chinese town of Wuhan in December 2019, the extreme acute respiratory syndrome develops SARS-CoV-2. The disease can dramatically progress from fever, toxin, shortness of the breath and smell and taste alterations to acute air distress, septic shock, multi-organ insufficiency and blood clots [8–10]. The lipidoma of the infected cells is considered to be remodelled with SARS-CoV and MERS-CoV. This study letter is therefore intended to provide and address details about reported differences in lipid metabolites in COVID-19 patients. Curcumin is an essential component in turmeric, also used in herbal medicine as a painkiller. It has broad biological qualities including anti-inflammatory and antioxidant function. The beta-coronavirus SARS-CoV-2 causes extreme pneumonitis. Inflammasomas are one of the key components of innate immunity, exacerbating inflammation by increasing the development of IL-1β and IL-18. Studies on viral infections revealed overactivity and therefore destructive and systemic inflammation in patients. Inflammasome was detected. Inflammasome NLRP3 has been shown to play a vital part in infectious disease pathogenesis. The distribution of SARS-CoV-2 in a number of cells can be associated with multiple findings that the inflammasome triggering by other coronaviruses is direct or indirect. Inflammasoma activation is likely to lead to cytokine storm development. In addition, the cardiovascular risk factor is known to be antiphospholipid (aPL) antibodies. Both target platelet membrane phospholipids are discharges by WBC (i.e. plasma B cells), resulting in the development of abnormal clots in the veins and/or arteries (thrombosis) (phlebitis). Therefore, in positive subjects with SARS-CoV-2 anticardiolipin antibodies (aCL IgG) profile (>15 U/mL) were found to be consistent with severe (e.g., breathing) disease although the previous reported history of thrombosis did not appear in those patients. ACL IgG may be a risk marker for COVID 19 patients, the reviewer concluded [11–16]. This form of ACE2 receptor can be located in cholesterol and sphingomyelin-rich lipid arrays. Researchers recently discovered that the binding field of the receptor directly binds to linoeic acid, a fatty acid noted for its pro-inflammatory activities. This is a feature that other SARS-CoVs and MERS-CoVs share. This must also be more unravelled on its biological relevance. It has been interesting to note that a variety of inquiries have found that COVID-19 patients have previously presented complications such as type 2 diabetes mellitus, hypertension and cardiovascular (CVD) diseases[2,4]. In addition, PLA research shows a near correlation between the seriousness of COVID-19 and the circulating fluids: a mixture of higher levels of atherogenic diglycerides and triglycerides, alterations in the PI signalling mechanism with lower levels of phosphatidylcholines[8] and sphingosine-1-phosphates (S1P). It is worth noting that patients reported decreased levels of PI and PC in erythrocytes following heart failure before the SARS-CoV-2 pandemic. S1P is also transported by HDL in plasma and can also be involved in shielding the lipoprotein against CVD [17–21].

Coronavirus 2019 (COVID-19) is an infectious disease with extreme coronavirus 2 acute respiratory syndrome, which has progressed to a pandemic. C5a and its C5aR1 receptor (also identified under CD88) play a significant part in inducing and sustaining multiple inflammatory reactions through the mobilisation and stimulation of neutrophils and monocytes [22–25]. This includes longitudinal analysis for immune reactions including phenotypic immune cell monitoring and analyses of the soluble factors involved at the different levels of the COVID-19 seriousness of patients, including paucisymptomas and pneumonia and acute respiratory

distress syndrome, in the blood and bronchoalveolar lavage fluid. Soluble C5a levels were increased according to COVID-19 gravity and C5aR1 receptor high expression levels were observed in blood and pulmonary myeloid cell, which supports the role of the C5a–C5aR1 axis in acute respiratory distress syndrome pathophysiology. The C5a-medicated recruiting and recruitment of human myeloid cells and inhibiting acute lung damage in micro-humans C5aR1 has been repaired by therapeutic monoclonal antibodies. These findings indicate that the C5a–C5aR1 axis blockade may be used to reduce myeloid cell penetration into compromised organs and avoid unnecessary pulmonary inflammation and endothelialitis related to acute respiratory distress in COVID-19 sufferers [26–28].

DISCUSSION

A conflict between human beings and SARS-CoV-2 viruses is taking place in global nations. Phylogenetic inspection of the entire virus showed that the newness of the virus is most similar to a SARS-like community (genus Betacoronavirus, subgenus Sarbecovirus). SARS-CoV-2 patients had a range of health incidents including fever, cough, myalgia or fatigue, dyspnea, even the symptom of acute respiratory arrest, acute heart attack, and secondary infection and a substantial number of critical patients were admitted to the intensive care centre (ICU) [3,6,8,29]. In addition to positive viral nuclear acid and representative pulmonary CT results, most single patients reported increases in neutrophil counts (NC), D-dimer, blood urea nitrogen and creatinine levels and lymphocyte counts (bilateral distribution of patchy shadows and ground glass opacity). Increased biomarkers linked to inflammation, including interleukin-6 (IL-6), C-reactive protein (CRP), ferroprotein, etc., were observed in patients obtained with COVID-19. However, there is no fully direct association between inflammatory markers and disease severity. This research has also studied retrospectively markers of blood inflammation in moderate, serious, and critical patients that may be of assistance in the early detection of severe or critical people and clinical intervention early on [6–10,30]. Specifically, in december of 2019 in Wuhan, China, extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads quickly across the globe hitting pandemic proportions by March 2020. In Italy 237,500 healthy adults of SARS-CoV-2 were reported in 34,405 patients who were dead from February to 17 June. In order to improve successful treatment, researchers and clinicians have been attempting to discover since December 2019 the pathogenic properties of the new disease caused by SARS-CoV-2, called COVID-19. Usually, significant pneumonia is occurring in approximately 30 percent of patients with inflammatory cascade hyperactivation and development into Acute Respiratory Disease (ARDS). At present, the inflammatory state of COVID 19 patients has remained at the forefront of most study reports. However, since the main target organ is the lung, the inflammatory state in the deep lung during various infection processes is important to consider. Restricted data are currently given in patients with COVID-19 for use with Bronchoscopy to prevent aerosol production, regarding alveolary inflammatory status[18,24,31–34].

REFERENCES:

[1] Saeedi-Boroujeni A, Mahmoudian-Sani M-R, Bahadoram M, Alghasi A. COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin? *Basic Clin Pharmacol Toxicol*. 2021;128(1):37-45. doi:10.1111/bcpt.13503

[2] Pimentel LL, Rodríguez-Alcalá LM. Cholesterol, inflammation, and phospholipids: COVID-19 share traits with cardiovascular disease. *Biochim Biophys Acta - Mol Cell Biol Lipids*. 2021;1866(1). doi:10.1016/j.bbalip.2020.158839

[3] Zhang D, Guo R, Lei L, et al. Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. *J Leukoc Biol*. 2021;109(1):13-22. doi:10.1002/JLB.4HI0720-470R
[4] Fois AG, Paliogiannis P, Scano V, et al. The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients. *Molecules*. 2020;25(23). doi:10.3390/molecules25235725
[5] Gong J, Dong H, Xia Q-S, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study. *BMC Infect Dis*. 2020;20(1). doi:10.1186/s12879-020-05681-5
[6] Haljasmägi L, Salumets A, Rumm AP, et al. Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19. *Sci Rep*. 2020;10(1). doi:10.1038/s41598-020-77525-w
[7] Lamb LE, Dhar N, Timar R, Wills M, Dhar S, Chancellor MB. COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). *Med Hypotheses*. 2020;145. doi:10.1016/j.mehy.2020.110375
[8] Pandolfi L, Fossali T, Frangipane V, et al. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome. *BMC Pulm Med*. 2020;20(1). doi:10.1186/s12890-020-01343-z
[9] Iacobellis G, Secchi F, Capitanio G, et al. Epicardial Fat Inflammation in Severe COVID-19. *Obesity*. 2020;28(12):2260-2262. doi:10.1002/oby.23019
[10] Bardin PG, Johnston SL. Attenuating COVID-19 infection and inflammation: Lessons from asthma. *Respirology*. 2020;25(12):1233-1234. doi:10.1111/resp.13961
[11] Krams IA, Luoto S, Rantala MJ, Jõers P, Krama T. COVID-19: Fat, obesity, inflammation, ethnicity, and sex differences. *Pathogens*. 2020;9(11):1-10. doi:10.3390/pathogens9110887
[12] Bellanti JA, Settipane RA. The allergist/immunologist, the Janus gatekeeper of inflammation, COVID-19 and beyond. *Allergy Asthma Proc*. 2020;41(6):395-396. doi:10.2500/AAP.2020.41.200084
[13] Wanderer JP, Nathan N. COVID-19 Coagulopathy and Inflammation: The Knowns and Unknowns. *Anesth Analg*. 2020;131(5):1323. doi:10.1213/ANE.0000000000005215
[14] Unudurthi SD, Luthra P, Bose RJC, McCarthy J, Kontaridis MI. Cardiac inflammation in COVID-19: Lessons from heart failure. *Life Sci*. 2020;260. doi:10.1016/j.lfs.2020.118482
[15] Norooznezhad AH, Hantoushzadeh S, Shamshirsaz AA. Empiric antibiotics in management of inpatient pregnant women infected with coronavirus disease 2019 (COVID-19): Focusing on inflammation and preterm labor. *Med Hypotheses*. 2020;144. doi:10.1016/j.mehy.2020.110269
[16] Tona F. MP, Plebani M, Gregori D, et al. "stay home stay safe?" Systemic inflammation in subjects undergoing routine hematology tests during the lockdown period of COVID-19. *Clin Chem Lab Med*. 2020;58(12):E315-E316. doi:10.1515/cclm-2020-1016
[17] Ogawa-Momohara M, Muro Y, Takeichi T, Akiyama M. Reducing immunosuppressant use in patients with chronic inflammation during the COVID-19 pandemic: Risks versus benefits. *J Cutan Immunol Allergy*. 2020;3(5):120-121. doi:10.1002/cia2.12132
[18] Pamukçu B. Inflammation and thrombosis in patients with COVID-19: A prothrombotic and inflammatory disease caused by SARS coronavirus-2. *Anatol J Cardiol*. 2020;24(4):224-234. doi:10.14744/AnatolJCardiol.2020.56727
[19] Ferreira C, Viana SD, Reis F. Gut microbiota dysbiosis–immune hyperresponse–inflammation triad in coronavirus disease 2019 (Covid-19): Impact of pharmacological and nutraceutical approaches. *Microorganisms*. 2020;8(10):1-29. doi:10.3390/microorganisms8101514

[20] Beltrán-García J, Osca-Verdegal R, Pallardó F V, et al. Oxidative stress and inflammation in covid-19-associated sepsis: The potential role of anti-oxidant therapy in avoiding disease progression. *Antioxidants*. 2020;9(10):1-20. doi:10.3390/antiox9100936
[21] Daneshkhah A, Agrawal V, Eshein A, Subramanian H, Roy HK, Backman V. Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients. *Aging Clin Exp Res*. 2020;32(10):2141-2158. doi:10.1007/s40520-020-01677-y
[22] Sheng CC, Sahoo D, Dugar S, et al. Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study). *Clin Cardiol*. 2020;43(10):1055-1063. doi:10.1002/clc.23451
[23] Ibrahim H, Perl A, Smith D, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. *Clin Immunol*. 2020;219. doi:10.1016/j.clim.2020.108544
[24] Kuchi Bhotla H, Kaul T, Balasubramanian B, et al. Platelets to surrogate lung inflammation in COVID-19 patients. *Med Hypotheses*. 2020;143. doi:10.1016/j.mehy.2020.110098
[25] Mozafari N, Azadi S, Mehdi-Alamdarlou S, Ashrafi H, Azadi A. Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin. *Med Hypotheses*. 2020;143. doi:10.1016/j.mehy.2020.110111
[26] Uzzan M, Soudan D, Peoc'h K, Weiss E, Corcos O, Treton X. Patients with COVID-19 present with low plasma citrulline concentrations that associate with systemic inflammation and gastrointestinal symptoms. *Dig Liver Dis*. 2020;52(10):1104-1105. doi:10.1016/j.dld.2020.06.042
[27] DiNicolantonio JJ, Barroso-Aranda J. Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. *Med Hypotheses*. 2020;143. doi:10.1016/j.mehy.2020.110051
[28] Gómez-Pastora J, Weigand M, Kim J, et al. Hyperferritinemia in critically ill COVID-19 patients – Is ferritin the product of inflammation or a pathogenic mediator? *Clin Chim Acta*. 2020;509:249-251. doi:10.1016/j.cca.2020.06.033
[29] Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. *Intensive Care Med*. 2020;46(6):1105-1108. doi:10.1007/s00134-020-06059-6
[30] Alrubayyi A. Intestinal attenuation of COVID-19 inflammation. *Nat Rev Immunol*. 2020;20(12):719. doi:10.1038/s41577-020-00466-y
[31] Qin L, Li X, Shi J, et al. Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan. *J Med Virol*. 2020;92(11):2684-2692. doi:10.1002/jmv.26137
[32] Xue G, Gan X, Wu Z, et al. Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19. *Int Immunopharmacol*. 2020;89. doi:10.1016/j.intimp.2020.107065
[33] Li C, Jiang J, Wang F, et al. Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients. *J Mol Cell Cardiol*. 2020;147:74-87. doi:10.1016/j.yjmcc.2020.08.008
[34] Vadukul P, Sharma DS, Vincent P. Massive pulmonary embolism following recovery from COVID-19 infection: inflammation, thrombosis and the role of extended thromboprophylaxis. *BMJ Case Rep*. 2020;13(9). doi:10.1136/bcr-2020-238168